Regeneron Pharmaceuticals, Inc. (REGN) stock
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/308% above fair value
$951.19−8.22 (-0.86%)
Close on Nov 12, 2026Market cap $98.40BP/E 21.0Yield –
Regeneron Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Regeneron Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was 28.5%. For fiscal 2025 it was 31.4%, against 31.1% the year before. The highest annual figure on record is 54.4% in fiscal 2012.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 31.4% | +0.3 |
| FY2024 | Dec 31, 2024 | 31.1% | +0.9 |
| FY2023 | Dec 31, 2023 | 30.1% | −5.5 |
| FY2022 | Dec 31, 2022 | 35.6% | −14.6 |
| FY2021 | Dec 31, 2021 | 50.2% | +8.9 |
| FY2020 | Dec 31, 2020 | 41.3% | +9.1 |
| FY2019 | Dec 31, 2019 | 32.3% | −15.2 |
| FY2018 | Dec 31, 2018 | 47.5% | +27.1 |
| FY2017 | Dec 31, 2017 | 20.4% | +2.0 |
| FY2016 | Dec 31, 2016 | 18.4% | +2.9 |
| FY2015 | Dec 31, 2015 | 15.5% | +3.5 |
| FY2014 | Dec 31, 2014 | 12.0% | −7.7 |
| FY2013 | Dec 31, 2013 | 19.7% | −34.8 |
| FY2012 | Dec 31, 2012 | 54.4% | +104.2 |
| FY2011 | Dec 31, 2011 | -49.7% | −27.0 |
| FY2010 | Dec 31, 2010 | -22.8% | −4.9 |
| FY2009 | Dec 31, 2009 | -17.9% | +15.3 |
| FY2008 | Dec 31, 2008 | -33.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 38.1% | −0.8 |
| Q2 FY2026 | Jun 30, 2026 | 30.2% | −7.6 |
| Q1 FY2026 | Mar 31, 2026 | 20.2% | −6.5 |
| Q4 FY2025 | Dec 31, 2025 | 21.7% | −2.5 |
| Q3 FY2025 | Sep 30, 2025 | 38.9% | +2.9 |
| Q2 FY2025 | Jun 30, 2025 | 37.9% | −2.5 |
| Q1 FY2025 | Mar 31, 2025 | 26.7% | +3.7 |
| Q4 FY2024 | Dec 31, 2024 | 24.2% | −9.5 |
| Q3 FY2024 | Sep 30, 2024 | 36.0% | +6.1 |
| Q2 FY2024 | Jun 30, 2024 | 40.4% | +9.7 |
| Q1 FY2024 | Mar 31, 2024 | 23.0% | −2.9 |
| Q4 FY2023 | Dec 31, 2023 | 33.8% | −1.3 |
| Q3 FY2023 | Sep 30, 2023 | 30.0% | −14.8 |
| Q2 FY2023 | Jun 30, 2023 | 30.7% | +0.8 |
| Q1 FY2023 | Mar 31, 2023 | 25.9% | −7.0 |
| Q4 FY2022 | Dec 31, 2022 | 35.1% | −10.0 |
| Q3 FY2022 | Sep 30, 2022 | 44.8% | −2.5 |
| Q2 FY2022 | Jun 30, 2022 | 29.8% | −30.5 |
| Q1 FY2022 | Mar 31, 2022 | 32.8% | −11.3 |
| Q4 FY2021 | Dec 31, 2021 | 45.0% | −2.4 |
| Q3 FY2021 | Sep 30, 2021 | 47.3% | +10.6 |
| Q2 FY2021 | Jun 30, 2021 | 60.3% | +14.3 |
| Q1 FY2021 | Mar 31, 2021 | 44.1% | +9.9 |
| Q4 FY2020 | Dec 31, 2020 | 47.4% | +4.9 |
| Q3 FY2020 | Sep 30, 2020 | 36.7% | −1.7 |
| Q2 FY2020 | Jun 30, 2020 | 46.0% | +33.7 |
| Q1 FY2020 | Mar 31, 2020 | 34.2% | +0.6 |
| Q4 FY2019 | Dec 31, 2019 | 42.5% | −0.1 |
| Q3 FY2019 | Sep 30, 2019 | 38.4% | +2.7 |
| Q2 FY2019 | Jun 30, 2019 | 12.2% | −22.1 |
| Q1 FY2019 | Mar 31, 2019 | 33.6% | +2.0 |
| Q4 FY2018 | Dec 31, 2018 | 42.6% | +31.6 |
| Q3 FY2018 | Sep 30, 2018 | 35.7% | +9.9 |
| Q2 FY2018 | Jun 30, 2018 | 34.3% | +7.9 |
| Q1 FY2018 | Mar 31, 2018 | 31.6% | +12.8 |
| Q4 FY2017 | Dec 31, 2017 | 11.0% | −9.7 |
| Q3 FY2017 | Sep 30, 2017 | 25.9% | – |
| Q2 FY2017 | Jun 30, 2017 | 26.4% | – |
| Q1 FY2017 | Mar 31, 2017 | 18.9% | – |
| Q4 FY2016 | Dec 31, 2016 | 20.6% | – |
See a number that looks wrong?